ResMed: Ma Activity

The leadership read

Selling MatrixCare removes ResMed's largest software-as-a-service business — a long-term care and post-acute EHR platform — from its operating portfolio. That is a material portfolio commitment, not a trim. MatrixCare was the anchor of ResMed's Software-as-a-Service segment, which the company had built through acquisition over several years as a hedge against hardware-cycle exposure. Divesting it to Frazier Healthcare Partners signals that ResMed is recentralizing around its core sleep and respiratory device business, accepting concentrated hardware-and-services revenue in exchange for a cleaner operating model. The strategic cost is real: the company sheds recurring software revenue and the patient-data adjacency that made post-acute EHR strategically attractive in the first place. This is one of twelve M&A signals we have tracked across sectors in the last 90 days, and the healthcare-adjacent subset — including Coral Connect's acquisition of AdvisorWoRx — reflects a consistent pattern: PE firms absorbing specialized vertical-software businesses that larger strategics are rationalizing out of diversified portfolios. The shape is recognizable: acquirer is a healthcare-specialist fund; the asset has embedded workflow relationships that compound slowly rather than growing through product-led velocity. Companies at this stage of portfolio contraction — shedding a vertical-software unit to refocus on medtech core — face concentrated demand for commercial leadership that can defend device-side margins without the cross-sell leverage a software platform previously provided, alongside product and clinical-data leadership that can rebuild software optionality natively rather than through acquisition.